Gene Therapy with CCL2 (MCP-1) Mutant Protects CVB3-induced Myocarditis by Compromising Th1 Polarization.

Yan Yue,Jun Gui,Wei Xu,Sidong Xiong

DOI: https://doi.org/10.1016/j.molimm.2010.11.018

IF: 4.174

2010-01-01

Molecular Immunology

Abstract:Viral myocarditis, which is most prevalently caused by Coxsackievirus B3 (CVB3) infection, affects about 5–20% of the world population and lacks efficient treatments. We previously reported that monocyte chemotactic protein-1 (MCP-1, CCL2) was significantly induced during CVB3 infection and greatly contributed to the myocardic inflammation and injury. Herein a CCL2 mutant with removed chemotactic activity was administrated and its therapeutic effect on CVB3-induced myocarditis was explored. A dominant negative CCL2 mutant, lacking the N-terminal amino acids 2–8 (CCL2Δ2–8), was genetically constructed and intramuscularly injected into BALB/c mice after CVB3 infection, severity of myocarditis was evaluated by weight loss, survival rate, serological indices and pathological observation. Systemic and local Th1/Th2 cytokine profiles were also assessed. Mice receiving pCCL2Δ2–8 exhibited a profound attenuation of myocarditis compared to pcDNA3.1 or non-treated mice, as evidenced by invariant body weight, decreased serum CK-MB level, reduced myocardial inflammatory infiltration and increased survival. This effect was not attributable to the efficient viral clearance, but associated with weakened Th1 immune responses, as evidenced by significantly reduced CD4+IFN-γ+ T cell frequency and Th1 cytokine level systemically and locally. Strategy of blocking in vivo CCL2 activity could effectively alleviate the severity of CVB3-induced myocarditis and may present an alternative therapeutic approach against viral myocarditis.